Neoadjuvant radiotherapy plus radical surgery for locally advanced stage III/IV oral cancer: Analysis of prognostic factors affecting overall survival

INTRODUCTION: In Senegal, breast cancer is the second female cancer and poses a major public health problem. The aim of this work was to assess prognostic factors in the progression of breast cancer in women. PATIENTS AND METHODS: This is a retrospective study carried out over a period of one year from January 1, 2008 to December 31, 2008 on all the women followed for breast cancer in the oncology department at the Joliot Curie Institute. Thus, 288 breast cancer patients were collected. RESULTS: The average age of our patients was 47.32 years. The average parity was 4.9 children per woman. Twenty-two or 7% of patients had a history of cancer. Clinically, the tumor size was classified as T4 in 180 patients, ie 81%. Lymph node involvement in 188 patients (65.2%). The most frequent histological type was invasive ductal carcinoma with 90.3% of cases. A predominance of grades SBRII and SBRIII was observed (respectively 41% and 46%). Hormone receptors (RH) were positive in eight cases (24%). Overexpression of the HER2 gene was found in only four out of 30 patients. The limits of the surgery were specified in 48 patients with invaded margins in seven patients (14.5%). The presence of vascular emboli was noted in 18 patients among the 29 whose research was carried out in 179 patients, ie 62%. At the time of the initial diagnosis, 45 patients or 19.7% of patients presented at least one distant metastasis. The majority of patients were received at an advanced stage (89%, classified between stage III and IV). Only one patient was received at stage I. Overall survival for breast cancer was 72% at 3 years and 30% at 5 years. The 5-year overall survival of patients with localized disease was 85% compared to 5% for patients with advanced stage. CONCLUSION: The prognostic factors are multiple and often pejorative in our patients with a predominance of young women, locally advanced cancers and aggressive biological forms.

Download Full-text

Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer

Seminars in Oncology ◽

10.1053/sonc.2002.34257 ◽

2002 ◽

Vol 29 (3 Suppl 12) ◽

pp. 10-16 ◽

Cited By ~ 3

Author(s):

Angela Davies ◽

David R. Gandara ◽

Primo Lara ◽

Zelanna Goldberg ◽

Peter Roberts ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Stage Iii ◽

Advanced Stage ◽

Therapeutic Approaches ◽

Small Cell Lung

Download Full-text

Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience

Tumori Journal ◽

10.1177/03008916211027627 ◽

2021 ◽

pp. 030089162110276

Author(s):

Adorni Marco ◽

Bazzurini Luca ◽

Lissoni Andrea Alberto ◽

Vecchione Francesca ◽

Negri Serena ◽

...

Keyword(s):

Overall Survival ◽

Neoadjuvant Chemotherapy ◽

Partial Response ◽

Vulvar Cancer ◽

Elderly Women ◽

Radical Surgery ◽

Locally Advanced ◽

Complete Response ◽

Tumor Burden ◽

Clinical Response Rate

Background: Squamous cell carcinoma of the vulva is a rare malignancy that affects elderly women. About one-third of vulvar cancers are diagnosed in an advanced stage, requiring extensive surgery. Neoadjuvant chemotherapy (NACT) has been introduced to reduce local tumor burden. In this retrospective study, we analyze the efficacy and toxicity of NACT followed by radical surgery. Methods: Patients with locally advanced vulvar cancer (LAVC) treated at our institution with neoadjuvant platinum and paclitaxel-based chemotherapy ± ifosfamide followed by surgery at our institution were retrospectively identified. Results: Fourteen patients (93%) completed NACT with tolerable toxicities (G3–G4 toxicity: 30%). Thirteen patients (87%) underwent surgery. The overall clinical response rate on vulvar disease was 66% (20% complete response, 46% partial response), confirmed by histopathologic analysis, while on inguinal lymph nodes it was 69% (23% complete response, 46% partial response). At the pathologic examination, all patients had negative surgical margins. Three out of 9 patients (33%) with lesions infiltrating the urethral meatus and 4 patients out of 7 (57%) with anal involvement did not require urethral amputation or colostomy, respectively, after NACT. No severe postoperative complications were described. Overall survival at 5 years was 60%, and median overall survival was 76 months. Conclusion: NACT followed by surgery in locally advanced vulvar cancer is well tolerated and allows surgical modulation.

Download Full-text

Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Radiology and Oncology ◽

10.1515/raon-2018-0009 ◽

2018 ◽

Vol 0 (0) ◽

Author(s):

Martina Vrankar ◽

Karmen Stanic

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Locally Advanced ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Term Survival ◽

Long Term Survival ◽

Stage Iii Nsclc

Abstract Background Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.

Download Full-text

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

PLoS ONE ◽

10.1371/journal.pone.0204490 ◽

2018 ◽

Vol 13 (10) ◽

pp. e0204490 ◽

Cited By ~ 4

Author(s):

Antoine Schernberg ◽

Laura Mezquita ◽

Angela Boros ◽

Angela Botticella ◽

Caroline Caramella ◽

...

Keyword(s):

Lung Cancer ◽

Prognostic Biomarker ◽

Locally Advanced ◽

Stage Iii ◽

Advanced Stage

Download Full-text

Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer

Seminars in Oncology ◽

10.1016/s0093-7754(02)90002-3 ◽

2002 ◽

Vol 29 (3) ◽

pp. 10-16 ◽

Cited By ~ 1

Author(s):

Angela Davies ◽

David R. Gandara ◽

Primo Lara ◽

Zelanna Goldberg ◽

Peter Roberts ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Stage Iii ◽

Advanced Stage ◽

Therapeutic Approaches ◽

Small Cell Lung

Download Full-text

Moist Exposed Burn Ointment Effectiveness for Capecitabine Associated Grade II and III Hand Foot Syndrome on Stage III Colonic

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2021.6959 ◽

2021 ◽

Vol 9 (B) ◽

pp. 971-974

Author(s):

Budhi Ida Bagus ◽

Nunik Agustriani ◽

Rieva Ermawan ◽

Suwardi Suwardi ◽

Amru Sungkar ◽

...

Keyword(s):

Single Agent ◽

Locally Advanced ◽

Common Adverse Effect ◽

Dose Intensity ◽

Stage Iii ◽

Advanced Stage ◽

Chemotherapy Agent ◽

Palmoplantar Erythrodysesthesia ◽

Hand Foot Syndrome ◽

Grade Ii

Background:Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine. Hand-foot syndrome of any grade is reported to affect 43% to 71% of patients treated with single-agent capecitabine chemotherapy. Although not life-threatening, it can have adverse effects on the quality of life (QoL) and daily living activities of a patient. Sometimes the dose interruptions and reductions required after observation of HFS can also impact on dose intensity and treatment outcomes. As an option for the treatment of this case, we would reported our preliminary study of the effectiveness of moist exposed burn ointment (MEBO) for stage II and III HFS. Methods: We will evaluate the clinical sign and symptoms of hand foot syndrome grade II and III associated with capecitabine as adjuvant chemotherapy agent on advanced stage colorectal cancer. All patients with HFS will treated with topical MEBO twice daily, the clinical improvement of the symptoms will be recorded. Results: We reported 8 cases of grade II and III hand foot syndrome, 2 patients were grade III HFS and the others were grade II. These symptoms occurred after 2 until 3 months after capecitabine administration for locally advanced (stage III) colonic adenocarsinoma. Topical MEBO were used twice a day for 3 months, pain reduction was achieved with no capicetabine dose interruption and reduction during chemotherapy period. Allergic reaction was not found during and after MEBO application in this case. Conclusion:Moist exposed burn ointment was an effective treatment option in managing hand foot syndrome, better option in reducing the pain without interrupting the capecitabine doses.

Download Full-text

Improved Overall Survival and Decreased Metastasis With Adjuvant 5-Fluorouracil and Platinum Chemotherapy After Definitive Concurrent Chemoradiotherapy for N3 Nasopharyngeal Cancer: A Registry-Based Analysis

10.21203/rs.3.rs-228154/v1 ◽

2021 ◽

Author(s):

Mu-Hung Tsai ◽

Shang-Yin Wu ◽

Tsung Yu ◽

Sen-Tien Tsai ◽

Yuan-Hua Wu

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Adjuvant Chemotherapy ◽

Distant Metastasis ◽

Concurrent Chemoradiotherapy ◽

Locally Advanced ◽

Nasopharyngeal Cancer ◽

Disease Free Survival ◽

Free Survival ◽

Risk Of Death

Abstract Background and purpose Concurrent chemoradiotherapy is the established treatment for locally advanced nasopharyngeal carcinoma (NPC). However, there is no evidence supporting routine adjuvant chemotherapy. We aimed to demonstrate the effect of adjuvant chemotherapy on survival and distant metastasis in high-risk N3 NPC patients. Materials and methods We linked the Taiwan Cancer Registry and Cause of Death database to obtain data. Clinical N3 NPC patients were divided as those receiving definitive concurrent chemoradiotherapy (CCRT) with adjuvant 5-fluorouracil and platinum (PF) chemotherapy and those receiving no chemotherapy after CCRT. Patients receiving neoadjuvant chemotherapy were excluded. We compared overall survival, disease-free survival, local control, and distant metastasis in both groups using Cox proportional hazards regression analysis. Results We included 431 patients (152 and 279 patients in the adjuvant PF and observation groups, respectively). Median follow-up was 4.3 years. The 5-year overall survival were 69.1% and 57.4% in the adjuvant PF chemotherapy and observation groups, respectively (p = 0.02). Adjuvant PF chemotherapy was associated with a lower risk of death (hazard ratio [HR] = 0.61, 95% confidence interval [CI]: 0.43–0.84; p = 0.003), even after adjusting for baseline prognostic factors (HR = 0.61, 95% CI: 0.43–0.86; p = 0.005). Distant metastasis-free survival at 12 months was higher in the adjuvant PF chemotherapy group than in the observation group (98% vs 84.8%; p < 0.001). After adjusting for baseline prognostic factors, adjuvant PF chemotherapy was associated with freedom from distant metastasis (HR = 0.11, 95% CI: 0.02–0.46; p = 0.003). Conclusion Prospective evaluation of adjuvant PF chemotherapy in N3 NPC patients treated with definitive CCRT is warranted because adjuvant PF chemotherapy was associated with improved overall survival and decreased risk of distant metastasis.

Download Full-text